benzylpenicillin
Small moleculeapproved
Approved
Sep 13, 1988
PENICILLIN G HYDRABAMINE, a semi-synthetic antibiotic, is used for the treatment of infections caused by susceptible, usually gram-positive, organisms. — NCATS
Clinical trial activity
6 trials · 8 clinical orgs · 6 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
3
Earliest trial started Jan 1, 2018 (NCT04215770)
Timeline
1980s
- Sep 13, 1988
Earliest FDA Approval
- Sep 13, 1988
Watson Pharmaceuticals — Marketing Organization
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Tyrosine-protein kinase JAK1ANTAGONIST
JAK1 antagonist
Approval history
- approvedSep 13, 1988
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O.CC4(C)S[C@@H]5[C@H](NC(=O)CC6=CC=CC=C6)C(=O)N5[C@H]4C(O)=O.CC(C)C7=CC=C8C(CC[C@H]9[C@](C)(CNCCNC[C@]%10(C)CCC[C@@]%11(C)[C@H]%10CCC%12=C%11C=CC(=C%12)C(C)C)CCC[C@]89C)=C7- Mol. weight
- 1265.751 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaBenzylpenicillin ↗
- NCATS667Y1107D3 ↗
- ChEMBLCHEMBL1126 ↗
- NCATS1C87B1N51X ↗
Also known as
- benzylpenicillin sodium
- benzylpenicillin sodium
- benzylpenicillin sodium
- e706
- e706
- penicillin g sodium
- penicillin g sodium
- penicillin g sodium
- penicillin g sodium
- penicillin g sodium, crystalline
- penicillin g sodium, crystalline
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06726395 | Phase 4 | Dec 31, 2024 | Lund University, Region Skane |
| NCT06616168 | Phase 1 | Sep 1, 2023 | Lviv National Medical University |
| NCT04876131 | Phase 4 | Jun 30, 2021 | Murdoch University, University of Melbourne |
| NCT04053140 | Phase 1 | Aug 31, 2019 | Imperial College London |
| NCT03632642 | Phase 4 | Sep 30, 2018 | University of Queensland |
| NCT04215770 | N/A | Jan 1, 2018 | Pakistan Army |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Imperial College London | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Lund University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Lviv National Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Murdoch University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Pakistan Army | Government | 1 | 1 | 1 | 2018 |
| Region Skane | Government | 1 | 1 | 1 | 2024 |
| University of Melbourne | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Queensland | Academic/Hospital | 1 | 1 | 1 | 2018 |
8 organizations
Page 1 / 1
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bristol-Myers Squibb | For profit | MKTG | — |
| Eci Pharmaceuticals Llc | For profit | MKTG | — |
| Novartis | For profit | MKTG | Feb 26, 2001 |
| Pharmacia & Upjohn | For profit | MKTG | — |
| Sandoz | For profit | MKTG | Feb 26, 2001 |
| Watson Pharmaceuticals | For profit | MKTG | Sep 13, 1988 |